Cited by 333Treatment of Major DepressionElectroconvulsive Therapy StudiesTryptophan and brain disorders

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class

Kim, Jean, Farchione, Tiffany, Potter, Andrew, Chen, Qi, Temple, Robert·2019·New England Journal of Medicine

DOI 10.1056/nejmp1903305

Open this paper in CoChat — free account

Abstract

Interview with Dr. Roy Perlis on esketamine as an option for treatment-resistant depression. (08:16)Download The FDA has approved esketamine, the first antidepressant in a new class, for treatment-resistant depression. The agency weighed the drug’s rapid onset of effect against its abuse potential, which led to a Risk Evaluation and Mitigation Strategy.

Integrity signals

Registry

Crossref · 10.1056/nejmp1903305

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Mortality in Mental Disorders and Global Disease Burden Implications: A Systematic Review and Meta-analysis
Walker, E. R., McGee, R. E., & Druss, B. G. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2502 · Cited by 2,976
Synaptic Mechanisms Underlying Rapid Antidepressant Action of Ketamine
Kavalali, E. T., & Monteggia, L. M. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040531 · Cited by 258
Treatment-resistant depression and suicidality
Bergfeld, I. O., Mantione, M., Figee, M., Schuurman, P. R., Lok, A., & Denys, D. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.016 · Cited by 256
Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications
Khin, N. A., Chen, Y., Yang, Y., Yang, P., & LAUGHREN, T. P. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06191 · Cited by 211

Show all 5 references

Sorted by citations

Items 201–300 of 333

Effects of esketamine on depression-like behavior and dendritic spine plasticity in the prefrontal cortex neurons of spared nerve injury-induced depressed mice
Huang, B., Li, X., Zheng, Y., Mai, Y., & Zhang, Z. (2024) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2024e13736 · Cited by 8
Novel treatments of depression: bridging the gap in current therapeutic approaches
Jagtiani, A. (2024) · Exploration of neuroscience · doi:10.37349/en.2024.00049 · Cited by 6
A Multimodal Preclinical Assessment of MDMA in Female and Male Rats: Prohedonic, Cognition Disruptive, and Prosocial Effects
Adam, A. S., LaMalfa, K. S., Razavi, Y., Kohut, S. J., & Kangas, B. D. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0049 · Cited by 6
Management of Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia
Wang, G., Han, C., Liu, C.-Y., Chan, S. S. M., Kato, T., Tan, W., Zhang, L., Feng, Y., & Ng, C. H. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s264813 · Cited by 6
Effect of Low-Dose Esketamine Combined with Propofol on Postoperative Fatigue in Colonoscopy: A Randomized Clinical Trial
Sun, X., Du, Q., Liang, Y., Tang, L., Wei, Q., Guo, P., & Liu, X. (2025) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s521961 · Cited by 5
Inflammatory response to repeated subcutaneous esketamine in treatment-resistant depression: The role of baseline C-reactive protein
Cavalcanti-Ribeiro, P., Souza, L. C. A. M. D., Tavares, V. D. D. O., de Almeida, R. N., Lima, N. B. D. M., Gonçalves, K. T. D. C., Lopes, E. I. T. C., Bolcont, R., de Brito, A. J. C., Falchi-Carvalho, M., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120877 · Cited by 4
Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder
Liu, R., Liu, N., Ma, L., Liu, Y., Huang, Z., Peng, X., Zhuang, C., Niu, J., Yu, J., & Du, J. (2024) · CNS Drugs · doi:10.1007/s40263-024-01123-x · Cited by 5
Real-World Effectiveness of Repeated Ketamine Infusions for Treatment-Resistant Bipolar Depression.
Fancy, F., Rodrigues, N. B., Vincenzo, J. D. D., Chau, E., Sethi, R., Husain, M. I., Gill, H., Tabassum, A., McKenzie, A., Phan, L., et al. (2023) · Focus · doi:10.1176/appi.focus.23021022 · Cited by 26
Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States
Harding, L., Joshi, K., Zhdanava, M., Shah, A., Voegel, A., Chen, C., & Pilon, D. (2024) · Drugs - Real World Outcomes · doi:10.1007/s40801-024-00425-2 · Cited by 6
Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database
Liu, R., Liu, C., Feng, D., Guo, T., & Wang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1414703 · Cited by 5
Ketamine Treatment in Depression: A Systematic Review of Clinical Characteristics Predicting Symptom Improvement
Lowe, D. J. E., Müller, D. J., & George, T. P. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200423094423 · Cited by 5
Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action
Irwin, M. N., & VandenBerg, A. (2021) · Mental Health Clinician · doi:10.9740/mhc.2021.05.200 · Cited by 7
Identification of New Ketamine Metabolites and Their Detailed Distribution in the Mammalian Brain
Vallianatou, T., Anselmo, C. D. S., Tsiara, I., Bèchet, N. B., Lundgaard, I., & Globisch, D. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00051 · Cited by 4
Esketamine Optimized the Efficacy of Dexmedetomidine in Treating Sleep Disorders with Comorbid Depression
Ding, Y., Wang, Z., Huang, J., Yi, Y., & Wu, Z. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s530265 · Cited by 4
Unveiling the enigma of anxiety disorders and depression: from pathogenesis to treatment
Pan, H., Xia, T., Zhang, Y., Zhang, H., Xu, M., Guo, J., Liu, Y., Bai, X.-Y., Liu, Q., Liu, W.-Z., et al. (2025) · Science China Life Sciences · doi:10.1007/s11427-025-3024-y · Cited by 5
Efficacy and safety of esketamine on major depression, postpartum depression and perioperative depression: a systematic review and meta-analysis
Huang, C., Hu, L., Wu, L., Geng, F., Wong, G. T. C., Zhang, Y., Reif, A., Bao, Y., Xue, Q., & Lü, L. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03320-6 · Cited by 11
Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States
Clemens, K., Zhdanava, M., Teeple, A., Voegel, A., Joshi, K., Shah, A., Chen, C., & Pilon, D. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.24240 · Cited by 5
Low dose oral ketamine treatment on post-traumatic stress disorder (PTSD) (OKTOP): An open-label pilot study
Quigley, B. L., Can, A., Dutton, M., Gallay, C. C., Forsyth, G., Jones, M., Randall, F., Wilson, P. A., Lagopoulos, J., & Hermens, D. F. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.01.003 · Cited by 4
Significance of NMDA receptor-targeting compounds in neuropsychological disorders: An in-depth review
Forouzanfar, F., Ahmadzadeh, A. M., Pourbagher‐Shahri, A. M., & Gorji, A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177690 · Cited by 4
Addiction of Hallucinogens, Dissociatives, Designer Drugs and “Legal Highs”: Update on Potential Therapeutic Use
Farré, M., Papaseit, E., Fonseca, F., & Torrens, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-36391-8_19 · Cited by 5
Patients with psychiatric disease: implications for anesthesiologists
Guthrie, D. B., & Richman, D. C. (2021) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000982 · Cited by 4
A Breakthrough in Understanding the Rapid Antidepressant Effect of Ketamine Based on Structural Analysis
Liu, H., Wu, X., Chen, J., & Fang, Y. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00794-6 · Cited by 4
Severe Hypotension With Concomitant Sodium-Glucose Co-Transporter-2 Inhibitor and Angiotensin Receptor-Neprilysin Inhibitor Therapy in a Patient With Heart Failure Reduced Ejection Fraction: A Case Report
Schumacher, C. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900221142686 · Cited by 4
Rapid Antidepressant-Like Potential of Chaihu Shugan San Depends on Suppressing Glutamate Neurotransmission and Activating Synaptic Proteins in Hippocampus of Female Mice
Lu, C., Gao, Z.-W., Xing, S., Wang, H. H., Huang, Y., Zhou, H., & Wu, L. (2024) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-024-3906-2 · Cited by 5
Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?
Bahji, A., Vázquez, G. H., & Zarate, C. A. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.12.069 · Cited by 5
Sleep alterations in treatment-resistant depression patients undergoing ketamine treatment
Kwaśny, A., Cubała, W. J., Włodarczyk, A., & Pastuszak, K. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00641-1 · Cited by 3
Esketamine relieves depressive-like behaviors in MPTP-induced Parkinson disease mice via GPR109A-dependent reduction of neuroinflammation
Wang, S., Song, W., Gao, Y., Tan, W., Ji, L., & Wang, C. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111595 · Cited by 3
Esketamine for postoperative sleep disturbance: clinical evidence, mechanisms, and future directions
Liu, Q., Liu, Y., Fu, Q., Gao, B., & Liu, Y. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1612230 · Cited by 6
Effectiveness of ketamine/esketamine in alleviating postoperative fatigue: a systematic review
Liu, Q., Liu, Y., Fu, Q., Gao, B., Ji, C., Xie, J., Yang, B., Xie, J., Alwesabi, A. K., & Liu, Y. (2025) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-025-02052-5 · Cited by 3
Ascorbic acid enhances antidepressant-like efficacy of esketamine: Hippocampal TARP-γ8-containing AMPA receptors mediate synaptic modulation
Ke, Z., Zhang, Y., Jiang, X., Luo, J., Chen, H., Ma, Y., Chen, Q., Zhao, L., & Cai, B. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00786 · Cited by 4
Self-citation
Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine
Dodds, C., Dawson, R. L., Lim, A., Tye, S. J., & Nasrallah, F. A. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251396255 · Cited by 4
From monoamine deficits to multiscale plasticity: twenty-five years of ketamine and the neurophysiology of depression
Bulek, D., & BaDour, S. (2026) · Journal of Neurophysiology · doi:10.1152/jn.00516.2025 · Cited by 3
Long-term quality of life after repeated ketamine infusions in anxious and nonanxious patients with depression
Liang, Y., You, Z., Chen, X., Liu, G., Li, W., Wang, C., Lan, X., Luo, Z., Mai, S., Zhang, F., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.084 · Cited by 3
Application of Real-World Data and the REWARD Framework to Detect Unknown Benefits of Memantine and Identify Potential Disease Targets for New NMDA Receptor Antagonists
Kern, D. M., Cepeda, M. S., Flores, C. M., & Wittenberg, G. M. (2021) · CNS Drugs · doi:10.1007/s40263-020-00789-3 · Cited by 3
Targeting Neuroplasticity for the Management of Pain and Agitation in Alzheimer’s Disease via Bergamot Nanotherapy
Scuteri, D., Tonin, P., Corasaniti, M. T., & Bagetta, G. (2022) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2203133 · Cited by 3
Examining memory reconsolidation as a mechanism of nitrous oxide’s antidepressant action
Williams, E., Taujanskaitė, U., Kamboj, S. K., Murphy, S. E., & Harmer, C. J. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-02049-0 · Cited by 3
Effects of Binaural Beat Music and Esketamine for ECT in the Treatment of Major Depressive Disorder: A Randomized Controlled Trial Protocol
Zhang, Y., Ke, Z., Luo, J., Chen, Q., Xu, X., Jiang, X., & Xiong, J. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s514640 · Cited by 4
Self-citation
Ketamine Plus Motivational Enhancement Therapy: Leveraging a Rapid Effect to Promote Enduring Change
Mathew, S. J., & Price, R. B. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19121242 · Cited by 3
Monoamine neurotransmitter-related gene-based genome-wide association study of low-dose ketamine in patients with treatment-resistant depression
Kao, C., Tsai, S., Su, T., Li, C., Lin, W.-C., Hong, C., Bai, Y., Tu, P., & Chen, M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251326939 · Cited by 2
Modeling the efficacy of a novel antidepressant zuranolone for major depressive disorder
Liu, J., Hong, L.-M., Qian, Y., Chen, R., & Lin, W.-W. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120158 · Cited by 2
Reverse Translation
Kangas, B. D. (2025) · Perspectives on Behavior Science · doi:10.1007/s40614-025-00478-w · Cited by 2
Comment on Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Canuso, C. M., Bossie, C. A., Fu, D., Lane, R., Doherty, T., Lignugaris, A., Fagiolini, A. M., Llorca, P., McIntyre, R. S., Reif, A., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250250 · Cited by 2
Hallucinogen use in the United States, 2021–2023: Diverging trends and subgroup patterns
Chen, J.-J., Berg, C. J., & Yang, Y. T. (2026) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2026.100410 · Cited by 2
The Potential Influence of Associated Antidepressants on the Pharmacokinetic Profile of Esketamine in Patients Affected by Treatment-resistant Depression
Alborghetti, M., Lionetto, L., Lombardozzi, G., Montaguti, L., Trovini, G., Donato, D., Costanzi, G., Bernardini, D. D., Catapano, F., Surano, M., et al. (2025) · Current Neuropharmacology · doi:10.2174/011570159x356952241216172603 · Cited by 3
Binding of esketamine to human serum albumin for clinical implications
Li, Y., Sun, F., Yu, J., Yu, L., Shao, W., & Zhu, Y. (2021) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1007/s10847-021-01090-6 · Cited by 2
Changes in cortical gene expression in major depressive disorders: More evidence implicating inflammatory-related pathways in disease etiology
Dean, B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817935-2.00037-4 · Cited by 2
New drugs in psychiatry - cariprazine, lurasidone, esketamine
Pożarowska, K., Rusinek, A., Rudziński, G., Soroka, E., & Masiak, J. (2021) · Current Problems of Psychiatry · doi:10.2478/cpp-2021-0010 · Cited by 2
Future of Pediatric Sedation
Miner, J. R. (2021) · Springer eBooks · doi:10.1007/978-3-030-58406-1_47 · Cited by 2
Ketamine modulates neural stem cell differentiation by regulating TRPC3 expression through the GSK3β/β-catenin pathway
She, Y., Pan, J., Peng, L., Ma, L., Guo, X., Lei, D.-X., & Wang, H.-Z. (2022) · NeuroToxicology · doi:10.1016/j.neuro.2022.10.018 · Cited by 2
Overview of ketamine for major depression: efficacy and effectiveness
Bahji, A., Vázquez, G. H., Brietzke, E. M., & Zarate, C. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00005-8 · Cited by 2
Will the promise of translational neuropsychopharmacology research ever deliver? The lion’s roar; the kitten’s purr
McGinty, J. F., Arango, V., Brady, K. T., Comer, S. D., Goldstein, R. Z., Nestler, E. J., Stoops, W. W., & Nader, M. A. (2024) · NPP—Digital Psychiatry and Neuroscience · doi:10.1038/s44277-024-00005-w · Cited by 1
Application of Anesthetic Agents in Depression
Vutskits, L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93273-8.00026-2 · Cited by 1
Dizocilpine derivatives as neuroprotective NMDA receptor antagonists without psychomimetic side effects
Konecny, J., Misiachna, A., Chvojková, M., Kletečková, L., Kolcheva, M., Novak, M., Prchal, L., Ladislav, M., Hemelíková, K., Netolický, J., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116981 · Cited by 1
Ketamine effects on resting state functional brain connectivity in major depressive disorder patients: a hypothesis-driven analysis based on a network model of depression
Recourt, K., van Gerven, J., Drenth, N., van der Grond, J., Nishigori, K., van der Wee, N. J., & Jacobs, G. E. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1531375 · Cited by 1
Ascorbic Acid and Esketamine for Mental Disorders in Women with Miscarriage: A Randomized Controlled Double-Blind Trial Protocol
Ke, Z., Zhang, Y., Cai, B., Luo, J., Ma, Y., Chen, Q., & Deng, L. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s516355 · Cited by 1
Self-citation
Effects of Esketamine on Post-Partum Depression in Patients With Different Personality Types Undergoing Caesarean Section: Randomised Controlled Trial
Luo, M., Tang, N., Guo, Y., Fan, D., & Wang, X. (2025) · Actas Españolas de Psiquiatría · doi:10.62641/aep.v53i4.1965 · Cited by 1
L-type voltage-dependent calcium channels in the ventromedial orbitofrontal and prefrontal cortices mediate the inhibitory effects of (S)-ketamine but not (R)-ketamine on marble burying in male mice
Deyama, S., Mishiro, K., Kunishima, M., & Kaneda, K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178301 · Cited by 1
The NMDA Receptor Antagonist Memantine Modulates Aging and Stress Resilience
Juozaityte, V., Pregnolato, C., Nørgaard, S., Rausch, D. M., McIntyre, R. L., Gerhart‐Hines, Z., Pers, T. H., Salcini, A. E., & Clemmensen, C. (2025) · Aging Cell · doi:10.1111/acel.70303 · Cited by 1
Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science
van Hoogdalem, M. W., Fu, D., Drevets, W. C., & Zannikos, P. (2026) · Clinical and Translational Science · doi:10.1111/cts.70527 · Cited by 2
Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions
Guidetti, C., D, M. F. M., & Papakostas, G. I. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03722-0 · Cited by 1
Psychedelics produce enduring enhancement of reward responsiveness in male rats
Thomas, C. W., LaMalfa, K. S., Whelan, T. P., Blackmore, T., Golden, C. T., Pizzagalli, D. A., Bergman, J., Gilmour, G., & Kangas, B. D. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02475-2 · Cited by 1
The role of nutrition in psychedelics clinical trials: Key considerations and recommendations for 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)
Mechlińska, A., Kwaśny, A., Pastuszak, M., & Cubała, W. J. (2026) · Nutritional Psychiatry · doi:10.1016/j.nupsyc.2026.100036 · Cited by 1
Learning From History to Shape Destiny
Meyer, R. E. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001107 · Cited by 1
Esketamina intranasal: un nuevo abordaje para el tratamiento de la depresión resistente al tratamiento
González-Pinto, A. M. (2020) · Psiquiatría Biológica · doi:10.1016/j.psiq.2020.01.001 · Cited by 1
New Progress in the Treatment of Refractory Depression with Esticketamine
孙, 诗. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.125592 · Cited by 1
“Drugs of Abuse” as a “New Antidepressant”: - A Review on Pharmacological Mechanisms, Antidepressant Effects, and Abuse Potential
An, Y., Park, S.-Y., & Kang, U. G. (2022) · 신경정신의학 · doi:10.4306/jknpa.2022.61.4.243 · Cited by 1
Medical Use of Cannabinoids and Psychedelic Compounds
Inserra, A., Gregorio, D. D., & Gobbi, G. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_141-1 · Cited by 1
Monitored anesthesia care: Dexmedetomidine-ketamine versus dexmedetomidine-propofol combination during burr-hole surgery for chronic subdural hematoma: A randomized trial
Kamel, A. A. F., Sayed, M. G. M. E., Naby, S. M. A., Elmesallamy, W. A. E. A., & Salem, D. A. E. (2024) · Perioperative Care and Operating Room Management · doi:10.1016/j.pcorm.2024.100398 · Cited by 1
Depresión mayor resistente. Terapia electroconvulsiva versus esketamina. ¿Cuál debería ser el orden? A propósito de un caso
Antón, B. U., Colmenares, M. O., & Aparicio, J. F. (2024) · Psiquiatría Biológica · doi:10.1016/j.psiq.2024.100488 · Cited by 1
Comparing Intravenous Racemic Ketamine and Intranasal Esketamine for Treatment-Resistant Depression: A Clinical Dilemma
Singh, B., Voort, J. L. V., & Kung, S. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_13 · Cited by 1
Ketamina eta esketaminaren erabilera depresioerresistentea tratatzeko: etorkizunerako erronkak
Elexpe, A., Bruzos-Cidón, C., Cabrera, M., Barreda‐Gómez, G., & Torrecilla, M. (2020) · EKAIA Euskal Herriko Unibertsitateko Zientzi eta Teknologi Aldizkaria · doi:10.1387/ekaia.21862
Algo más que monoaminas en el tratamiento de la depresión: Mecanismos neurobiológicos emergentes de los antidepresivos del siglo XXI
González, C. Á., Zaragozá, C., & Lopez-Munoz, F. J. (2020) · Revista de Investigación y Educación en Ciencias de la Salud (RIECS) · doi:10.37536/riecs.2020.5.2.214 · Cited by 2
Gold Nanoparticles Improve Clinical Parameters and Reduce Neurological Alterations in Sepsis-Induced Mice
Ferreira, J. P. S., Bella, D. D., Andreotti, D. Z., Cortes, B. F. S., de Carvalho, M. H. C., Kawamoto, E. M., & Rodrigues, S. F. (2023) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2023.3502 · Cited by 1
Die Therapie-resistente Depression
Erfurth, A. (2019) · psychopraxis neuropraxis · doi:10.1007/s00739-019-00590-y
Use of Esketamine in Pain Patients
Gevirtz, C. M. (2019) · Topics in Pain Management · doi:10.1097/01.tpm.0000617888.48477.cd
Ketamine, Esketamine, and A New Generation of Antidepressants
Wilkinson, S. T., & Kitay, B. M. (2020) · Psychiatric Annals · doi:10.3928/00485713-20200113-02
Novel therapeutic drug targets for bipolar disorder
Rosenblat, J. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819182-8.00037-5
Esketamine in Treatment Resistant Depression: The Way to Remission
Facucho-Oliveira, J., Esteves-Sousa, D., Prates, B. V. D. S., Neves, R., & Varandas, P. (2021) · Revista Portuguesa de Psiquiatria e Saúde Mental · doi:10.51338/rppsm.2021.v.i1.174
Emergence of Ketamine as a Rapid Acting Antidepressant: Mechanistic Insights and Future Directions
Singh, A., & Bedi, P. M. S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.99765
Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine
Garakani, A. (2021) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000593
Mood Disorders
Schwartz, E. R., Sabbag, S. A., Buford, U., Kieffer, L., & Allespach, H. H. (2022) · Springer eBooks · doi:10.1007/978-3-030-54441-6_33
Kids and drugs
Hodge, B., & Marsh, A. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-818954-2.00018-3
Ketamine for suicidal ideation
Giorgi, R. D. (2022) · BMJ · doi:10.1136/bmj.o74
KETAMINE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER AND ITS POTENTIAL FOR ABUSE
Freitas, D. V., Fernandes, C. P., Teixeira, R. J., Soares, C., Carneiro, S., & Jorge, B. (2019) · doi:10.26226/morressier.5d1a035857558b317a13f645
Characterizing ketamine-induced dissociation using human intracranial neurophysiology: brain dynamics, network activity, and interactions with propofolPreprint
Tian, F., Lewis, L. D., Zhou, D. W., Balanza, G. A., Paulk, A. C., Zelmann, R., Peled, N., Soper, D. J., Mercado, L. A. S. C., Peterfreund, R. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.02.490333
Mood Disorders
Schwartz, E. R., Sabbag, S. A., Buford, U., Kieffer, L., & Allespach, H. H. (2020) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_33-3
Pharmacological management of neuropsychiatric symptoms in geriatric traumatic brain injury: a scoping review
Goh, C. L., Cheng, J. T., Palit, M., Costello, S., & Barton, D. A. (2023) · Brain Injury · doi:10.1080/02699052.2023.2166115
Anesthetic Concerns in Psychiatric Disease
Martinez-Baladejo, M. T., Liongson, F. A. Z., Wong, D., Spoleti, C., Suyumov, D., Menghani, S. V., McCarthy, C., Divito, A. J., Daniel, S. V., Salpekar, S., et al. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.110173 · Cited by 1
-
(2021) · Romanian Journal of Psychiatry & Psychotherapy · doi:10.37897/rjpp.2021.3.3
Ketamine and Nitrous Oxide
Janski, A. M., Hristidis, V. C., Zorumski, C. F., & Conway, C. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00064-6
Medical Use of Cannabinoids and Psychedelic Compounds
Inserra, A., Gregorio, D. D., & Gobbi, G. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_141-2
The man who is confused about his identity
Chen, S. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108623872.002
Ketamine in psychiatry
Pham, G. S., & Mathew, S. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18496-3.00014-8
Dizocilpine derivatives with neuroprotective effect lacking the psychomimetic side effectsPreprint
Konecny, J., Misiachna, A., Chvojková, M., Kletečková, L., Kolcheva, M., Novák, M., Prchal, L., Ladislav, M., Hemelíková, K., Netolický, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.17.599304
Chapter 21. Ketamine and Esketamine
Mathai, D. S., & Mathew, S. J. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as21
Precision Obstetric Anesthesia and Analgesia: An Attempt to Assess the Emerging Modalities within the Fundamental Framework
Li, J., & Leffert, L. R. (2024) · Journal of Pain Research · doi:10.2147/jpr.s473488
Medical Use of Cannabinoids and Psychedelic Compounds
Inserra, A., Gregorio, D. D., & Gobbi, G. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_141
2013-2024 YILLARI ARASINDA FDA ONAYI ALMIŞ ANTİDEPRESANLAR VE YENİ ANTİDEPRESAN İLAÇ GELİŞTİRME ÇALIŞMALARI
Karacık, M., & Aksöz, B. E. (2024) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.33483/jfpau.1487644
Glutamatergic Changes Induced by Stress in the Brain and Effects of Rapid-Acting Antidepressants
Mingardi, J., & Musazzi, L. (2024) · Springer eBooks · doi:10.1007/978-3-031-32035-4_35-1
Nissl stain expression in the neonatal mice occipital cortex after prenatal ketamine exposure
Najm, M. S. (2024) · Epitheorese Klinikes Farmakologias kai Farmakokinetikes – Greek Edition · doi:10.61873/raln7719

Authors: Kim, J., Farchione, T., Potter, A., Chen, Q., & Temple, R.
Affiliations: United States Food and Drug Administration (US)
ORCID: Potter, Andrew
Chen, Qi
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2019-07-04
Volume: 381
Issue: 1
Pages: 1-4
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmp1903305
OpenAlex: W2946133992
Cited by: 333
References: 5
Citations by year: 2026: 26 · 2025: 47 · 2024: 56 · 2023: 37 · 2022: 55 · 2021: 51 · 2020: 48 · 2019: 13
FWCI: 25.88
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords: esketamine, treatment-resistant depression, FDA drug approval, NMDA receptor antagonists, antidepressants, abuse liability, risk evaluation and mitigation strategy
MeSH terms: Antidepressive Agents, Humans, Ketamine, United States, United States Food and Drug Administration, Drug Approval

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks